TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update
Provided By PR Newswire
Last update: Apr 1, 2025
Phase 3 IFx-2.0 accelerated approval trial as adjunctive therapy with Keytruda®
(pembrolizumab) in 1st line therapy for advanced Merkel cell carcinoma (MCC)
planning to initiate enrollment in Q2 2025
